CZ297680B6 - Farmaceutický prostredek s obsahem protilátek anti-CD40L nebo jejich derivátu - Google Patents

Farmaceutický prostredek s obsahem protilátek anti-CD40L nebo jejich derivátu Download PDF

Info

Publication number
CZ297680B6
CZ297680B6 CZ0244499A CZ244499A CZ297680B6 CZ 297680 B6 CZ297680 B6 CZ 297680B6 CZ 0244499 A CZ0244499 A CZ 0244499A CZ 244499 A CZ244499 A CZ 244499A CZ 297680 B6 CZ297680 B6 CZ 297680B6
Authority
CZ
Czechia
Prior art keywords
patient
cd40l
antibody
nephritis
antibodies
Prior art date
Application number
CZ0244499A
Other languages
Czech (cs)
English (en)
Other versions
CZ244499A3 (cs
Inventor
L. Kalled@Susan
W. Thomas@David
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of CZ244499A3 publication Critical patent/CZ244499A3/cs
Publication of CZ297680B6 publication Critical patent/CZ297680B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CZ0244499A 1997-01-10 1997-12-31 Farmaceutický prostredek s obsahem protilátek anti-CD40L nebo jejich derivátu CZ297680B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3467397P 1997-01-10 1997-01-10

Publications (2)

Publication Number Publication Date
CZ244499A3 CZ244499A3 (cs) 1999-10-13
CZ297680B6 true CZ297680B6 (cs) 2007-03-07

Family

ID=21877889

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ0244499A CZ297680B6 (cs) 1997-01-10 1997-12-31 Farmaceutický prostredek s obsahem protilátek anti-CD40L nebo jejich derivátu

Country Status (19)

Country Link
US (2) US20030031668A1 (enExample)
EP (2) EP1357131A3 (enExample)
JP (1) JP2001508441A (enExample)
KR (2) KR20000070034A (enExample)
CN (2) CN1572325A (enExample)
AU (1) AU5709798A (enExample)
BR (1) BR9714523A (enExample)
CA (1) CA2277222A1 (enExample)
CZ (1) CZ297680B6 (enExample)
EA (2) EA006314B1 (enExample)
EE (1) EE9900273A (enExample)
HU (1) HUP0000833A3 (enExample)
IL (1) IL130784A0 (enExample)
IS (1) IS5100A (enExample)
NO (1) NO993274L (enExample)
NZ (1) NZ337072A (enExample)
PL (1) PL190663B1 (enExample)
TR (7) TR200001249T2 (enExample)
WO (1) WO1998030240A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (en) 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
CN100352497C (zh) * 1998-04-03 2007-12-05 达特茅斯学院理事 应用特异性结合cd40cr(cd40 配体)的抗体抑制体液免疫
IL126681A0 (en) * 1998-10-21 1999-08-17 Opperbas Holding Bv Treatment of trauma-related conditions
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
US7507706B1 (en) 1998-12-14 2009-03-24 Genetics Institute, Llc Cytokine receptor chain
US6171795B1 (en) * 1999-07-29 2001-01-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to CD40ligand
US20010055593A1 (en) * 2000-03-14 2001-12-27 Joseph Sypek Use of rapamycin and agents that inhibit B7 activity in immunomodulation
AU8867501A (en) * 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
WO2002022212A2 (en) * 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
MX361174B (es) 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
CN100369932C (zh) * 2005-04-07 2008-02-20 苏州大学 抗人cd154单克隆抗体及其应用
US9044459B2 (en) 2008-12-05 2015-06-02 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
EP2367849B1 (en) * 2008-12-05 2017-11-01 ALS Therapy Development Institute Method for the treatment of neurodegenerative diseases
US20130310266A1 (en) * 2010-09-03 2013-11-21 Immport Therapeutics, Inc. Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
CA2958578A1 (en) 2014-08-21 2016-02-25 The General Hospital Corporation Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
AU2016317768A1 (en) * 2015-08-31 2018-02-22 Merck Patent Gmbh Methods for the modulation of LGALS3BP to treat systemic lupus erythematosus
EP3630843A2 (en) 2017-05-24 2020-04-08 ALS Therapy Development Institute Therapeutic anti-cd40 ligand antibodies
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
AU2022218137A1 (en) 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2026092377A1 (zh) * 2024-10-28 2026-05-07 信达生物制药(苏州)有限公司 用cd40l抗体治疗自身免疫病

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009812A1 (en) * 1991-11-15 1993-05-27 The Trustees Of Columbia University In The City Of New York MURINE MONOCLONAL ANTIBODY (5c8) RECOGNIZES A HUMAN GLYCOPROTEIN ON THE SURFACE OF T-LYMPHOCYTES
WO1996023071A2 (en) * 1995-01-26 1996-08-01 Bristol-Myers Squibb Company MONOCLONAL ANTIBODIES SPECIFIC FOR DIFFERENT EPITOPES OF HUMAN gp39 AND METHODS FOR THEIR USE IN DIAGNOSIS AND THERAPY

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
AU1748897A (en) * 1996-01-16 1997-08-11 Biogen, Inc. Therapeutic applications of T-BAM (CD40-L) technology to treat inflammatory kidney diseases
AU2593997A (en) * 1996-03-21 1997-10-10 Trustees Of Columbia University In The City Of New York, The Craf1 (traf-3) isoforms and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009812A1 (en) * 1991-11-15 1993-05-27 The Trustees Of Columbia University In The City Of New York MURINE MONOCLONAL ANTIBODY (5c8) RECOGNIZES A HUMAN GLYCOPROTEIN ON THE SURFACE OF T-LYMPHOCYTES
WO1996023071A2 (en) * 1995-01-26 1996-08-01 Bristol-Myers Squibb Company MONOCLONAL ANTIBODIES SPECIFIC FOR DIFFERENT EPITOPES OF HUMAN gp39 AND METHODS FOR THEIR USE IN DIAGNOSIS AND THERAPY

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
G. EARLY ET AL: "Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis ...", THE JOURNAL OF IMMUN., vol. 157, no 7, 1 October 1996, ... *
MOHAN C ET AL: "interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis", JOURNAL OF IMMUN. 154 (3), 1995, ... *

Also Published As

Publication number Publication date
TR200001249T2 (tr) 2000-11-21
JP2001508441A (ja) 2001-06-26
US20030031668A1 (en) 2003-02-13
EP0948355A1 (en) 1999-10-13
KR20000070034A (ko) 2000-11-25
CN1247472A (zh) 2000-03-15
CN1572325A (zh) 2005-02-02
KR20050089165A (ko) 2005-09-07
TR200001251T2 (tr) 2000-09-21
TR200001250T2 (tr) 2001-03-21
IS5100A (is) 1999-06-30
HUP0000833A2 (en) 2000-07-28
WO1998030240A1 (en) 1998-07-16
PL190663B1 (pl) 2005-12-30
TR200001247T2 (tr) 2002-06-21
PL334495A1 (en) 2000-02-28
EA006314B1 (ru) 2005-10-27
EA200501076A1 (ru) 2006-06-30
EA199900636A1 (ru) 2000-02-28
EE9900273A (et) 2000-02-15
NO993274L (no) 1999-09-10
HUP0000833A3 (en) 2001-09-28
NZ337072A (en) 2000-12-22
TR199902191T2 (xx) 1999-12-21
BR9714523A (pt) 2000-05-02
US20070190053A1 (en) 2007-08-16
NO993274D0 (no) 1999-07-01
TR200001248T2 (tr) 2000-07-21
CZ244499A3 (cs) 1999-10-13
IL130784A0 (en) 2001-01-28
EP1357131A3 (en) 2004-02-11
CA2277222A1 (en) 1998-07-16
AU5709798A (en) 1998-08-03
EP1357131A2 (en) 2003-10-29
TR200001246T2 (tr) 2000-07-21
KR100618081B1 (ko) 2006-08-30

Similar Documents

Publication Publication Date Title
CZ244499A3 (cs) Použití sloučeniny anti-CD40L pro výrobu léku pro léčení imunokomplexových poškození
WO1998030240A9 (en) Treatment of lupus nephritis with anti-cd40l compounds
KR102276161B1 (ko) 항체 제형 및 방법
KR100575069B1 (ko) 역적응성 면역 반응, 특히 이식 거부반응을 예방하기 위한ｃｄ40:ｃｄ154 결합 저해제의 용도
EP0966302B1 (en) Methods of therapeutic administration of anti-cd40l compounds
HUP0001263A2 (hu) Eljárások anti-CD4OL vegyületek gyógyászati alkalmazásaira
HK1062829A (en) Treatment of lupus nephritis with anti-cd4ol compounds
AU2920002A (en) Treatment of lupus nephritis with Anti-CD40L compounds
WO2023185720A1 (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
WO2023160517A1 (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
HK1024424B (en) Methods of therapeutic administration of anti-cd40l compounds

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20081231